New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court and agreed to pay 45 million to resolve its criminal and civil liability in the company's promotion of its prescription drug Megace ES for uses not approved as safe and effective by the Food and Drug Administration (FDA) and not covered by federal health care programs.